Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: SAGE-217 does well in phase 3 clinical trial

Posted by Hugh on January 10, 2019, at 10:03:10

In reply to SAGE-217 does well in phase 3 clinical trial, posted by Hugh on January 10, 2019, at 9:35:57

This clinical trial was for postpartum depression. The positive results mean that it's likely that SAGE-217 will be approved by the FDA later this year. If this happens, it can be prescribed off-label for major depressive disorder, bipolar I/II, and insomnia. (There are currently SAGE-217 clinical trials underway for these disorders.)

If it's approved by the FDA, SAGE-217 will be the first truly new class of antidepressant to appear since the SSRIs were introduced over thirty years ago.

Based on the results of earlier clinical trials, it appears that SAGE-217 might only have to be taken once a month, or even less frequently.




Post a new follow-up

Your message only Include above post

Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.


Start a new thread

Google www
Search options and examples
[amazon] for

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Hugh thread:1102732